In this installment of our 2021 ASH Annual Meeting Podcast series, Contributing Editor Dr. Brad Kahl has a conversation with Contributing Editor Dr. Frederick Locke about his work on one of the plenary abstracts that will be presented at the 2021 ASH Annual Meeting. The abstract presents an analysis of the ZUMA-7 trial of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma.
For coverage of the plenary scientific session, including this abstract and many other sessions, check www.ashpublications.org/ashnewsdaily throughout the meeting.       
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/